InsiderTrades.com logo
Exposed: 10 CENT Crypto to Explode April 20th?
From True Market Insiders   |   Ad
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
Click For My #1 FREE Crypto for 2024
Holger Wesche net worth and biography
  • Phone
  • Email
  • Website

Holger Wesche Biography and Net Worth

Insider of Harpoon Therapeutics
Dr. Wesche joined Harpoon Therapeutics with 20 years of biotech experience focused on target discovery and validation as well as drug development in the fields of oncology and inflammation. Prior to joining Harpoon in early 2015, he was responsible for the development and cross-functional coordination of the next generation BiTE platform, Amgen’s T-cell engaging antibody platform. He also led drug discovery projects in multiple therapeutic areas through pre-clinical development. Dr. Wesche is co-author and inventor of numerous publications and US patents. Dr. Wesche received his PhD, summa cum laude, in biochemistry and Immunology from the University of Hannover, Germany.

What is Holger Wesche's net worth?

The estimated net worth of Holger Wesche is at least $144,617.85 as of July 1st, 2021. Dr. Wesche owns 6,285 shares of Harpoon Therapeutics stock worth more than $144,618 as of April 26th. This net worth approximation does not reflect any other investments that Dr. Wesche may own. Learn More about Holger Wesche's net worth.

How do I contact Holger Wesche?

The corporate mailing address for Dr. Wesche and other Harpoon Therapeutics executives is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Harpoon Therapeutics can also be reached via phone at (650) 443-7400 and via email at [email protected]. Learn More on Holger Wesche's contact information.

Has Holger Wesche been buying or selling shares of Harpoon Therapeutics?

Holger Wesche has not been actively trading shares of Harpoon Therapeutics during the past quarter. Most recently, Holger Wesche sold 1,000 shares of the business's stock in a transaction on Thursday, July 1st. The shares were sold at an average price of $140.00, for a transaction totalling $140,000.00. Following the completion of the sale, the insider now directly owns 6,285 shares of the company's stock, valued at $879,900. Learn More on Holger Wesche's trading history.

Who are Harpoon Therapeutics' active insiders?

Harpoon Therapeutics' insider roster includes Georgia Erbez (CFO), Ansbert Gadicke (Major Shareholder), and Holger Wesche (Insider). Learn More on Harpoon Therapeutics' active insiders.

Are insiders buying or selling shares of Harpoon Therapeutics?

In the last twelve months, Harpoon Therapeutics insiders bought shares 1 times. They purchased a total of 21,397,205 shares worth more than $492,135,715.00. The most recent insider tranaction occured on March, 11th when Major Shareholder Merck & Co., Inc. bought 21,397,205 shares worth more than $492,135,715.00. Insiders at Harpoon Therapeutics own 17.0% of the company. Learn More about insider trades at Harpoon Therapeutics.

Information on this page was last updated on 3/11/2024.

Holger Wesche Insider Trading History at Harpoon Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/1/2021Sell1,000$140.00$140,000.006,285View SEC Filing Icon  
4/1/2021Sell1,000$204.50$204,500.006,131View SEC Filing Icon  
1/4/2021Sell1,000$183.80$183,800.00View SEC Filing Icon  
7/1/2020Sell1,000$162.00$162,000.006,266View SEC Filing Icon  
5/11/2020Sell100$140.70$14,070.005,801View SEC Filing Icon  
5/8/2020Sell100$140.00$14,000.005,801View SEC Filing Icon  
4/28/2020Sell125$140.50$17,562.505,391View SEC Filing Icon  
1/2/2020Sell1,000$144.00$144,000.006,266View SEC Filing Icon  
See Full Table

Holger Wesche Buying and Selling Activity at Harpoon Therapeutics

This chart shows Holger Wesche's buying and selling at Harpoon Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Harpoon Therapeutics Company Overview

Harpoon Therapeutics logo
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Read More

Today's Range

Now: $23.01
Low: $23.01
High: $23.01

50 Day Range

MA: $22.89
Low: $22.34
High: $23.01

2 Week Range

Now: $23.01
Low: $3.11
High: $23.21

Volume

N/A

Average Volume

1,516,200 shs

Market Capitalization

$389.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.11
Exposed: 10 CENT Crypto to Explode April 20th?
From True Market Insiders   |   Ad
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
Click For My #1 FREE Crypto for 2024